ReviewInfluenza and other respiratory viruses2013
Newer influenza antivirals, biotherapeutics and combinations.
Review in Influenza and other respiratory viruses, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review of respiratory viral pathogens identified in adults with community-acquired pneumonia in Europe.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2017Pooled it
- Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015Trial
- Identification of Natural Terpenoid Compounds as Potential Inhibitors of Nucleoprotein of Influenza A Virus usingMedicinal chemistry (Shariqah (United Arab Emirates)) · 2025Article
- Preclinical and clinical developments for combination treatment of influenza.PLoS pathogens · 2022Review
- Secondary Structure of Influenza A Virus Genomic Segment 8 RNA Folded in a Cellular Environment.International journal of molecular sciences · 2022Article
- The 1918 Influenza Pandemic and Its Legacy.Cold Spring Harbor perspectives in medicine · 2020Review
- Seasonal and pandemic influenza: 100 years of progress, still much to learn.Mucosal immunology · 2020Review
- The 1918 influenza pandemic: 100 years of questions answered and unanswered.Science translational medicine · 2019Review
- Effective in Vivo Targeting of Influenza Virus through a Cell-Penetrating/Fusion Inhibitor Tandem Peptide Anchored to the Plasma Membrane.Bioconjugate chemistry · 2018Article
- Host-pathogen kinetics during influenza infection and coinfection: insights from predictive modeling.Immunological reviews · 2018Review
- In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses.Journal of medicinal chemistry · 2018Article
- A travelling camper with a spiking fever, headache, myalgia, hepatitis, and intracellular inclusions.The Lancet. Infectious diseases · 2017Article
- Identification of Polo-like kinases as potential novel drug targets for influenza A virus.Scientific reports · 2017Article
- Antivirals against animal viruses.Biochemical pharmacology · 2017Review
- Quantifying the therapeutic requirements and potential for combination therapy to prevent bacterial coinfection during influenza.Journal of pharmacokinetics and pharmacodynamics · 2017Article
- Antiviral Treatments.Clinics in chest medicine · 2017Review
- Influenza A Virus Nucleoprotein: A Highly Conserved Multi-Functional Viral Protein as a Hot Antiviral Drug Target.Current topics in medicinal chemistry · 2017Review
- Antisense Oligonucleotides Targeting Influenza A Segment 8 Genomic RNA Inhibit Viral Replication.Nucleic acid therapeutics · 2016Article
- Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers.Molecular pharmacology · 2016Article
- OX40 ligand newly expressed on bronchiolar progenitors mediates influenza infection and further exacerbates pneumonia.EMBO molecular medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This summary provides an overview of investigational antiviral agents for influenza and of future directions for development of influenza therapeutics. While progress in developing clinically useful antiviral agents for influenza has been generally slow, especially with respect to seriously ill and high-risk patients, important clinical studies of intravenous neuraminidase inhibitors, antibodies and drug combinations are currently in progress. The current decade offers the promise of developing small molecular weight inhibitors with novel mechanisms of action, including host-directed therapies, new biotherapeutics and drug combinations, that should provide more effective antiviral therapies and help mitigate the problem of antiviral resistance. Immunomodulatory interventions also offer promise but need to be based on better understanding of influenza pathogenesis, particularly in seriously ill patients. The development of combination interventions, immunomodulators and host-directed therapies presents unique clinical trial design and regulatory hurdles that remain to be addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.